Key Documents

Crystal Violet Solution

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₂₅H₃₀ClN₃

CAS Number:

548-62-9

Molecular Weight:

407.98

UNSPSC Code:

12171500

NACRES:

NA.47

PubChem Substance ID:

329815275

MDL number:

MFCD00011750

Beilstein/REAXYS Number:

3580948

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

form

solution

Quality Level

500

shelf life

Expiry date on the label

IVD

for in vitro diagnostic use

concentration

2.3%

technique(s)

microbe id | staining: suitable

pH

4.6

application(s)

hematology
histology

storage temp.

room temp

SMILES string

[Cl-].CN(C)c1ccc(cc1)\C(c2ccc(cc2)N(C)C)=C3/C=C\C(C=C3)=[N+](/C)C

InChI

1S/C25H30N3.ClH/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6;/h7-18H,1-6H3;1H/q+1;/p-1

InChI key

ZXJXZNDDNMQXFV-UHFFFAOYSA-M

Description

Application

Intended for use in the Gram Stain Procedure No. HT90.

Other Notes

Contains 2.3% certified crystal violet, 0.1% ammonium oxalate and 20% ethyl alcohol, SD3A.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	V5265	32675	C6158
Sigma-Aldrich HT90132 Crystal Violet Solution	Sigma-Aldrich V5265 Crystal Violet Solution	Sigma-Aldrich 32675 Crystal Violet	Sigma-Aldrich C6158 Crystal Violet
technique(s) microbe id \| staining: suitable	technique(s) microbe id \| staining: suitable	technique(s) -	technique(s) -
concentration 2.3%	concentration 1%	concentration -	concentration -
form solution	form aqueous solution	form powder	form powder
application(s) hematology histology	application(s) diagnostic assay manufacturing hematology histology	application(s) diagnostic assay manufacturing hematology histology	application(s) diagnostic assay manufacturing hematology histology
IVD for in vitro diagnostic use	IVD -	IVD -	IVD -
shelf life Expiry date on the label	shelf life -	shelf life -	shelf life -

Still not finding the right product?

Explore all of our products under Crystal Violet Solution

pictograms

GHS02,GHS08,GHS07

signalword

Warning

hcodes

H226,H319,H351,H412

pcodes

P202 - P210 - P233 - P273 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Flam. Liq. 3

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

100.0 °F - closed cup

flash_point_c

37.8 °C - closed cup

ppe

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000460792

0000352766

0000262892

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling.

Chia-Hsun Fang et al.

Journal of biomedical science, 27(1), 42-42 (2020-03-15)

The underlying mechanism involved in ovarian cancer stemness and chemoresistance remains largely unknown. Here, we explored whether the regulation of c-Kit and plasma membrane prohibitin (PHB) affects ovarian cancer stemness and chemotherapy resistance. Mass spectrum analysis and an in vitro

Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR.

Bin Xiao et al.

Cell reports, 31(4), 107571-107571 (2020-04-30)

Mechanistic target of rapamycin complex 1 (mTORC1) is a master modulator of cellular growth, and its aberrant regulation is recurrently documented within breast cancer. While the small GTPase Rheb1 is the canonical activator of mTORC1, Rheb1-independent mechanisms of mTORC1 activation

Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming.

Chao Wan et al.

Science advances, 6(13), eaay9789-eaay9789 (2020-04-02)

Radiotherapy (RT) is routinely used in cancer treatment, but expansion of its clinical indications remains challenging. The mechanism underlying the radiation-induced bystander effect (RIBE) is not understood and not therapeutically exploited. We suggest that the RIBE is predominantly mediated by

View All Related Papers

Global Trade Item Number

SKU	GTIN
HT90132-1L	04061833835487

Questions

Reviews

No rating value